Esketamine: Treatment-Resistant Depression, Supervision, Safety and Recovery

Spravato contains esketamine, an NMDA receptor antagonist related to ketamine. It is used for selected adult depression indications. Its mechanism differs from that of SSRIs and SNRIs, but a different mechanism does not make it appropriate for every person whose mood remains low. Specialist assessment and a workable treatment plan are essential. [1]

Ask the clinician to identify the exact product and intended indication. Descriptions such as ketamine therapy can refer to different medicines, routes and regulatory situations. The name alone does not establish that the proposed service follows the approved Spravato model. A clear explanation should cover both what is being offered and what evidence supports it.

Current US labeling permits Spravato for adult treatment-resistant depression either alone or with an oral antidepressant. The European authorization cited here describes use with an SSRI or SNRI after at least two antidepressant treatments have not worked in the current moderate-to-severe depressive episode. The US monotherapy option should not automatically be transferred to another jurisdiction. [2] [3]

Ask which local indication applies and how previous treatments have been assessed. Bring the medicines tried, duration, response and reasons for stopping where known. A treatment that could not be tolerated and one that was taken adequately without sufficient benefit may raise different clinical questions. Do not diagnose treatment resistance from a count of prescriptions alone.

In the United States, Spravato has a separate indication, with an oral antidepressant, for depressive symptoms in adults with major depressive disorder and acute suicidal thoughts or behavior. Its effectiveness in preventing suicide or reducing suicidal behavior has not been demonstrated. Improvement after a dose does not remove the need for hospitalization when that is clinically indicated. [4]

If you are at immediate risk of harming yourself or cannot stay safe, seek emergency help rather than waiting for an esketamine assessment. A specialist treatment appointment is not a crisis-response plan. Ask the team how risk will be assessed between sessions and who will respond to urgent concerns.

A useful assessment reviews the diagnosis, previous treatment, current medicines and medical history. Tell the clinician about bipolar symptoms, psychosis, substance-use problems and earlier self-harm. Esketamine is not automatically a treatment for every condition that can include depression, and the evidence for one indication should not be generalized to all of them.

Ask what other explanations or treatments have been considered and why the proposed plan fits your situation. Bring your own priorities as well as symptom scores. Being able to work, care for yourself or participate in relationships may matter alongside changes on a rating scale. The assessment should also address practical barriers to attending monitored sessions.

Under the US REMS program, treatment occurs in a certified healthcare setting. The patient uses the spray under supervision and is monitored for at least two hours because of sedation, dissociation, respiratory depression and misuse risks. The clinician decides when discharge is appropriate; two hours is a minimum observation requirement, not an automatic promise of readiness to leave. [5]

Ask the service about its monitoring arrangements and emergency capability. Confirm how much time to allow and who will accompany you afterward. Do not obtain a device to use independently at home or assume a video consultation provides the same observation. This guide does not teach self-administration outside the authorized setting.

The clinic should provide instructions about food, drink, other nasal medicines and the treatment day. Follow those instructions and tell staff if they could not be followed. Arrange transport home. After treatment, do not drive, operate machinery or undertake tasks requiring full alertness until the next day after a restful night’s sleep. [1]

Plan ordinary responsibilities in advance, including childcare, work and any journey home. Do not assume that feeling well enough to leave the clinic means you can drive. Ask whom to contact if a symptom develops later and what information a person accompanying you should have. Practical planning is part of safe treatment, not a minor administrative detail.

Some people feel detached from their body, thoughts or surroundings during treatment. Dizziness, sleepiness and a spinning sensation can also occur. Tell the supervising clinician when an experience is frightening or you cannot stay awake. The intensity of an altered experience should not be treated as proof of a better antidepressant response. [6]

Ask how the team will help you during the session and how benefit will be assessed afterward. You do not need to produce a particular emotional experience for treatment to be considered meaningful. Describe both the immediate effects and your functioning between visits. A dramatic session and a sustained improvement in depression are different observations.

Esketamine can raise blood pressure. Certain blood-vessel abnormalities, a history of bleeding in the brain and other significant cardiovascular circumstances can make treatment unsuitable or require particular caution. The clinician needs your full history and should assess blood pressure before and after administration. Severe chest pain, breathlessness or neurological symptoms needs urgent attention. [2] [3]

Tell the team about blood-pressure medicines, stimulants and other prescriptions, including recently stopped products. Do not change them yourself to obtain a more favorable reading before an appointment. Ask what happens if a session is postponed for safety reasons and how your depression care will continue in the meantime.

Esketamine has potential for misuse and dependence. A history of alcohol or drug problems should be discussed openly so the clinician can assess suitability and monitoring. The supervised setting is part of managing these risks; it does not mean that the medicine is incapable of causing harm. [5]

Explain prior nonmedical ketamine use, cravings for an altered state or concerns about losing control. Do not supplement supervised treatment with products obtained elsewhere. Ask how mental health and addiction care will be coordinated. A substance-use history should lead to a careful discussion of benefit and risk rather than pressure to conceal information.

Spravato is not an approved general detoxification medicine. Its depression indication does not establish that it treats alcohol, opioid or benzodiazepine withdrawal. A person with both depression and addiction needs a separate assessment of withdrawal risk and evidence-based continuing addiction treatment. Research involving ketamine in other settings should not be presented as proof that this product is a standard addiction treatment.

Ask which part of your care addresses depression and which addresses substance use. Do not abruptly stop alcohol, sedatives or an established opioid-treatment medicine to prepare for a session without clinical advice. Our co-occurring-needs overview discusses the need for coordination without promising that COGNIFUL provides esketamine or every type of medical detoxification.

Approved esketamine nasal spray and compounded ketamine products are not the same medicine or regulatory proposition. FDA reiterated in 2026 that ketamine is not FDA-approved for psychiatric disorders, while Spravato has specific indications and restricted supervised administration. A product offered online should not borrow Spravato’s approval claims. [7]

Ask a service to name the medicine, route, authorization and monitoring model. Do not assume that a nasal spray, lozenge or injection described as similar has equivalent evidence, dosing or safety. This distinction is particularly important when comparing a monitored clinical treatment with a product sent home for unsupervised use.

Alcohol and other sedating medicines can add to safety concerns. Tell the clinician about opioids, benzodiazepines, sleep medicines, stimulants and all other products. Pregnancy requires prompt specialist discussion, and breastfeeding is not recommended during treatment under the cited US patient information. Do not alter another prescription without coordination. [1]

Nausea, vomiting, headache, unusual taste and nasal discomfort can occur. Persistent thinking or memory difficulties and urinary symptoms should also be reported. Ask what should be expected briefly after a session and what requires further assessment. A serious symptom should not be dismissed as simply part of a ketamine experience. [6]

The treatment schedule should be reviewed according to the indication, response and tolerability. Ask when the initial course will be assessed and what would justify continuing, changing frequency or stopping. Improvement is not guaranteed, and an initial response does not mean that follow-up becomes unnecessary. [8]

Keep observations about mood, functioning and safety between sessions. Discuss what psychological care and other support continue regardless of the decision about esketamine. Ending supervised sessions should be planned with the team; do not interpret it as automatically stopping every oral medicine as well. Different parts of the treatment plan need their own instructions.

If a session is missed, contact the service rather than trying to obtain or use medication elsewhere. Worsening depression needs review, and immediate danger requires emergency care. A plan should identify who responds between sessions and how information is shared with your regular mental health clinician. [1]

Before travel or transfer, ask whether treatment can continue safely and what alternatives are available if it cannot. Confirm the arrangements rather than assuming another clinic will use the same protocol. The medication-review checklist can help organize questions about prior treatment, current symptoms, practical access and the next stage.

Can Spravato be taken without an oral antidepressant?

Current US treatment-resistant-depression labeling allows this, but other indications and jurisdictions differ. Do not stop an oral prescription without a clinical decision.

Does it replace hospitalization for suicidal risk?

No. Emergency assessment and hospitalization remain necessary when clinically indicated.

Can I use it at home?

Spravato is administered under clinical supervision with observation. It is not a take-home self-treatment.

1. MedlinePlus: Esketamine nasal spray.
2. Manufacturer: Current US indications and safety information.
3. EMA: Spravato.
4. Manufacturer: MDD indication and limitations regarding suicide prevention.
5. Manufacturer: Supervised treatment and REMS requirements.
6. Manufacturer: Safety and tolerability.
7. FDA: Ketamine and esketamine regulatory distinctions, June 2026.
8. Manufacturer: Treatment planning and review.

Educational information only. Local authorization, product information and specialist assessment determine treatment. Inclusion is not a statement that COGNIFUL offers Spravato. Return to the medication library.